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The use of viruses as oncolytic agents
for tumor therapy was first described
several decades ago, using a variety of
viruses, including adenovirus, influenza
virus, mumps virus, and Newcastle dis-
ease virus, among others, in a number of
diverse cancer indications (reviewed by
Mullen and Tanabe, 2002, and Kirn,
2000; Asada, 1974). These initial human
trials met with limited durable responses,
likely due to a number of reasons, includ-
ing a poor understanding of molecular
virology, inconsistent preparations of
pure, well-characterized high-titer virus
formulations, and inadequately con-
trolled trials. Thus, this approach of
“virotherapy” was largely abandoned and
somewhat forgotten. However, the con-
vergence in the ensuing years of the
fields of molecular biology and virology
provided a fertile ground for the under-
standing required to genetically engineer
viruses and restrict their replication to
cells with defects in cell cycle control
pathways typical of cancer cells.
Frank McCormick and colleagues
pioneered a novel paradigm for cancer
therapy in 1996 (Bischoff et al., 1996) by
describing an approach to restrict the
productive lytic infection of adenoviruses
to cells having inactivated p53, a defect
that is ubiquitous among tumor cells.The
“oncolytic” adenovirus ONYX-015—orig-
inally called dl1520 by its creators
(Barker and Berk, 1987)—is deleted of
the viral E1b 55K gene. In order to under-
stand how ONYX-015 propagates selec-
tively in tumor cells, a short primer in
adenovirus biology is in order. The aden-
ovirus early region one (E1) has 2
genes, E1a and E1b, which encode a
number of proteins whose function it is to
initiate the process of making the infect-
ed cell a good host, so that the virus can
replicate its DNA, synthesize structural
“coat” proteins, assemble progeny virus
particles, lyse the cell, and start the
same process all over again in neighbor-
ing cells. The adenovirus E1a proteins
are the first viral gene expressed follow-
ing infection, and have several functions,
including activating the expression of all
of the other viral early genes (i.e., viral
proteins with enzymatic activity
expressed prior to viral DNA replication),
and mediating entry of the host cell into
S phase through binding of pRb. In so
doing, E1a liberates the E2F transcrip-
tion factor from the pRb-E2F complex,
and E2F subsequently activates the
expression of multiple cellular genes
required for progression into the cell
cycle. As a consequence of E2F activa-
tion, apoptosis is induced; fortunately for
adenoviruses, however, they evolved the
E1b gene, which encodes proteins that
suppress induction of both p53-depen-
dent and independent apoptosis. In par-
ticular, the E1b 55K protein binds to p53
together with another viral protein
expressed from the viral E4 gene,
E4orf6, and exports p53 to the cyto-
plasm, where it is degraded. Yet another
E4-encoded protein cooperates with
E2F to activate the expression of Ad E2.
Thus, the adenovirus E1 region proteins,
together with a portion of the E4 pro-
teins, inactivate the pRb and p53 tumor
suppressor proteins in order to mediate
entry of normal resting host cells into S
phase and suppress induction of apopto-
sis, thereby promoting viral DNA replica-
tion and completion of the virus life cycle.
In formulating the oncolytic virus
concept, McCormick reasoned that the
pathways that are inactivated in normal
cells infected by adenovirus (i.e., pRb
and p53) are strikingly similar to those
that are inactivated by tumor cells
(McCormick 2000). Thus, adenoviruses
deleted of the E1b 55K gene, like dl1520,
should establish productive infection in
cancer cells in which p53 was inactivat-
ed, but not in normal cells whose ability
to regulate p53 was intact. Indeed, this
was shown to be the case in comparing
dl1520 productive infection between nor-
mal and several established tumor cell
lines, and ONYX-015—as well as a new
field of developing cancer cell-selective
replicating viruses—was (re-)born.
In the development of ONYX-411
described in this issue of Cancer Cell,
Leisa Johnson and colleagues (Johnson
et al., 2002) have dramatically improved
upon the concept of ONYX-015. In the
process, they have created a highly
sophisticated recombinant adenovirus
that may make systemic administration
of selectively replicating viruses for the
treatment of metastatic malignancies a
more realistic possibility. Productive
infection of ONYX-411 was designed to
be restricted to cells having defects in
the pRb pathway, a phenotype common
to nearly all human cancers (Hanahan
and Weinberg, 2000). ONYX-411 repli-
cation was shown to occur at near wild-
type Ad levels in multiple human cancer
cell lines in vitro, but was essentially non-
cytotoxic in several cultured primary nor-
mal human epithelial cells. The inability
of ONYX-411 to establish productive
infection in normal human cells was a
result of an inability of the virus to medi-
ate efficient entry of these cells into S
phase. Notably, ONYX-015 was consis-
tently observed to be attenuated in
human tumor cells, as compared to
ONYX-411 and wild-type Ad. This obser-
vation may be due to another function of
the Ad E1B 55K protein, to facilitate
selective nucleocytoplasmic transport of
viral mRNA late in the infectious cycle.
How was the replication of ONYX-
411 engineered to be so tightly con-
trolled? By two means: first, by regulat-
ing the expression of both the viral E1a
and E4 genes; and second, by construct-
ing redundant controls into the expres-
sion and activities of these viral proteins.
The expression of the Ad E1 and E4
genes in ONYX-411 is controlled by
replacing the native viral promoters with
the human E2F promoter. The E2F pro-
moter has been shown by others to be
selectively active in tumor cells in vivo,
which typically contain “high free-E2F”
levels, and its function is linked directly to
the pRb status of the cell. Importantly,
the conserved region (CR) 2 of E1a,
which corresponds to its high affinity
binding pRb binding portion that medi-
(Re-)Engineering tumor cell-selective replicating adenoviruses:
A step in the right direction toward systemic therapy
for metastatic disease
An approach combining redundant controls to restrict the productive infection of adenoviruses to cells that are disrupted
in the pRb pathway—a hallmark of human cancer—has resulted in a novel oncolytic virus that may be well suited for sys-
temic administration to treat metastatic disease.
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ates release of E2F, is deleted in ONYX-
411. Thus, the CR2− deleted E1A protein
expressed by ONYX-411 in normal cells
is largely unable to break up the pRB-
E2F protein complex.The combination of
a tumor-specific promoter at each end of
the virus together with an E1a protein
unable to mediate S phase entry was
shown to be necessary to derive a virus
with the degree of restriction to cancer
cell lines that was observed with ONYX-
411.
What clinical advantage could
ONYX-411 confer as compared to the
ONYX-015 prototype? Theoretically,
ONYX-411 may be better suited for
applications, like metastatic disease,
requiring systemic virus administration.
As the mechanism of selection for virus
replication is operative post virus
absorption, both normal and cancer cells
are infected following intravenous virus
(IV) administration. Thus, the therapeutic
index of selectively replicating viruses
can be defined by their ability relative to
wild-type virus to establish productive
infection in human cancer cells, as com-
pared to normal primary cells. The thera-
peutic index for ONYX-411 was
observed to be quite high, and in some
cases it was 1000-fold less cytotoxic
than wild-type Ad in normal cells. Yet,
ONYX-411 consistently replicated to
wild-type virus levels in multiple cancer
cell lines. Based on observations in pre-
clinical studies performed in mice receiv-
ing high IV doses of ONYX-411, includ-
ing an absence of acute hepatotoxicity,
and reduction of established subcuta-
neous tumors correlating with increased
survival time, further testing, including
possibly human clinical trials, is warrant-
ed.
As cancer is primarily a disseminat-
ed disease, new therapeutic agents must
be able to provide durable systemic
responses against metastatic disease
originating from primary tumors of
diverse origin. For a virus to have sys-
temic activity, it must do three things
effectively, including: (1) gain access to
the tumors; (2) replicate and spread with-
in the tumor; and (3) kill the tumor cells,
either directly or indirectly. High doses (4
× 109 plaque forming units) of ONYX-411
given IV were shown to elicit no more
acute toxicity in immunocompetent mice
than PBS. Thus, since it is expected that
comparatively higher doses would corre-
late with higher amounts of virus access-
ing tumor cells following IV administra-
tion, in terms of each of these three cri-
teria, ONYX-411 would appear to be a
significant improvement upon ONYX-
015.
Are adenoviruses the optimal plat-
form for tumor-selective replicating virus-
es? The encouraging successes of
ONYX-015 in early- and mid-phase clini-
cal trials, particularly when combined
with conventional chemotherapy (Khuri
et al., 2000; Reid et al., 2001)—as well
Ad 2/5 (dl 309); ONYX-015; IIII
Ad 2/5 (dl 309); ONYX-411
Ad5; 01/PEME; NA
Ad 5; CG 7060; III
Ad 5; CG 7870; III
Ad5; CG 8900; NA
Ad5; Ad5-∆24RGD; NA
HSV-1; G207; III
HSV-1/HSV-2; NV1020; I
NDV; PV701; I
Reovirus; Reolysin; III
VSV; NA; NA
Rhinovirus/poliovirus intergeneric
recombinant; PV1(RIPO); NA
Measles (MV-Ed); I
13
4
5
6
7
8
9
10
11
12
13
14
15
16
p53−
TSP (E2F), pRb−
p53−
TSP (PSA)
TSP (PSA, Probasin)
TSP (AFP)
pRb−, integrin+ cells
Deficient PKR response, intracellular nucleotide
pools
Not determined (safe in human vaccine trials)
Activated ras, deficient PKR responsea
Activated ras, deficient PKR response
Activated ras, deficient PKR response
CD155 Poliovirus receptor; activated ras, 
deficient PKR responsea
Activated ras, deficient PKR responsea
Head and neck cancer, colorectal liver
metastases, advanced solid cancers
Cervical cancer xenografts (preclinical studies)
Several cancer xenografts (preclinical studies)
Early-stage prostate cancer
Hormone-refractory prostate cancer
Hepatocellular carcinoma (preclinical studies)
Ovarian (preclinical studies)
Malignant glioma
Colorectal liver metastases
Advanced solid cancers
Malignant glioma, prostate, advanced solid
cancers
Melanoma xenografts (preclinical studies)
Malignant glioma (preclinical studies)
Ovarian cancer
Parent virus; name (if available);
phase(s) of ongoing human clinical
trials for replication-selective viruses
Disease indication Virus replication-permissive tumor cell phenotype Reference
NA: Not applicable. TSP: Tissue Specific Promoter, used in the construction of the replication-selective virus. Responsiveness of the TSP indicated.
aPossible mechanism for virus replication selectivity; actual mechanism not demonstrated
1Khuri et al. (2000). Nat. Med. 6, 879885; 2Reid et al. (2001). Proc. Am. Soc. Clin. Oncol. 20, 549a; 3Nemunaitis et al. (2001). Gene Ther. 8, 746759; 4Johnson
et al. (2002) Cancer Cell 1, this issue; 5Ramachandra et al. (2001). Nat. Biotechnol. 19, 10351041; 6Rodriguez et al. (1997). Cancer Res. 57, 25592563; 7Yu
et al. (1999). Cancer Res. 59, 42004203; 8Li et al. (2001). Cancer Res. 61, 64286436; 9Bauerschmitz et al. (2002). Cancer Res. 62, 12661270; 10Mineta et al.
(1995). Nat. Med. 1, 938943; 11Cozzi et al. (2001). FASEB 15, 13061308; 12Pecora et al. (2002). JCO 20, 22512266; 13Norman et al. (2000). J. Clin. Inves. 105,
10351038; 14Stojdl et al. (2000). Nat. Med. 6, 821825; 15Gromeier et al. (2000). Proc. Natl. Acad. Sci. USA 97, 68036808; 16Grote et al. (2001). Blood 97,
37463754.
Table 1. A partial list of replication-selective viruses in development
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as the controversy over the requirement
for a defective p53 pathway to support
the replication selectivity of ONYX-015—
stimulated the development of numerous
additional oncolytic virus platforms. The
controversy surrounding the inactivated-
p53 requirement for ONYX-015 replica-
tion has been somewhat resolved
through studies demonstrating that a
subset of tumor cells contain a wild-type
p53 gene, yet are functionally p53 inac-
tive, due to inactivation of the “upstream”
p14arf, resulting in the accumulation of
mdm2, which binds p53 and targets it for
degradation, much in the same way as
does the adenovirus 55K protein
(McCormick, 2000; Ries et al., 2000).
While improved conditionally replicative
adenoviruses like ONYX-411 and others
(Li et al., 2001; Ramachandra et al.,
2001) have been developed, the ques-
tion still remains whether oncolytic
agents developed from other virus gen-
era will be more efficacious for local-
regional or systemic applications.Table 1
summarizes some other viruses in devel-
opment. The properties of these viruses
in terms of the expression of their cog-
nate receptors on various tumor cell
types, reproductive cycle time, yield,
cytotoxicity, and selectivity cover a broad
spectrum. Importantly, the issue of virus-
specific immune responses will need to
be addressed in order to repeatedly
administer any of these viruses intra-
venously. Another important issue relat-
ed to some of these viruses may be their
possible safety risk; in several instances,
viruses are being used without genetic
modification—such as deleting critical
virus regulatory genes—suggesting the
possibility of in vivo selection of virulent
phenotypes. For these or any oncolytic
viruses to eventually gain FDA approval
and become the standard of care will
require continued refinement and test-
ing, both in preclinical models and in
safety and efficacy trials in humans.
Nevertheless, the complete makeover
that ONYX-015 has received in the
design and development of ONYX-411
would appear to be a step in the right
direction toward oncolytic viruses
becoming useful therapies for the treat-
ment of selected cancers.
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For decades we have been attempting to
understand the basis of drug resistance
manifested by so many cancers. Even
tumors never previously exposed to anti-
cancer agents often already show intrin-
sic drug resistance, suggesting that
gene mutations driving tumor develop-
ment do not automatically confer resis-
tance to anticancer agents. In two recent
papers, Lowe and collaborators (Schmitt
et al., 2002a, 2002b) convincingly show
that in a lymphoid mouse tumor model,
drug resistance can be conferred not
only by lesions in the apoptotic pathway
but also, surprisingly, by mutations in the
senescence pathway. The realization
that an intact senescence pathway can
contribute to the success of chemothera-
py may have profound consequences for
the treatment of cancer patients.
Several mechanisms can contribute
to drug resistance. Cytotoxic drugs, at
the moment still the backbone for treat-
ment of disseminated cancer, almost
invariably damage DNA or interfere with
DNA replication or chromosomal segre-
gation. One way cells can prevent killing
by anticancer drugs is to expel the drugs
from the cell by transporters. Even low
amounts of these transporters substan-
tially decrease the sensitivity of cells to
cytotoxic drugs (Allen et al., 2000, and
references therein). However, this does
not explain why tumors often are inher-
ently resistant to anticancer agents. One
has to assume that this tolerance arises
as a side effect of the genetic alterations
that drive the tumorigenic process.
Indeed, mutations interfering with apop-
tosis can contribute both to tumor growth
and confer resistance to chemotherapy
in a mouse lymphoma model (Schmitt et
al., 1999). However, clinical practice
teaches that tumors with clear defects in
the apoptotic machinery are not neces-
Senescence: a companion in chemotherapy?
Mouse lymphoma model points to an unsuspected role of drug-induced “senescence.”
